SRR33532767
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.570
- E2F_TARGETS+0.520
- G2M_CHECKPOINT+0.500
- MYC_TARGETS_V1+0.460
- DNA_REPAIR+0.360
- MITOTIC_SPINDLE+0.260
- WNT_BETA_CATENIN_SIGNALING+0.250
- MTORC1_SIGNALING+0.240
- NOTCH_SIGNALING+0.190
- OXIDATIVE_PHOSPHORYLATION+0.150
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.480
- MYOGENESIS-0.430
- UV_RESPONSE_DN-0.400
- ANGIOGENESIS-0.390
- HYPOXIA-0.350
- COAGULATION-0.330
- KRAS_SIGNALING_UP-0.320
- COMPLEMENT-0.260
- PANCREAS_BETA_CELLS-0.260
- APICAL_JUNCTION-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 504282dd-4fef-4f70-a709-6a545d00a263 | — | — | 0.909 |
| 2 | TCGA-66-2757-01A-01R-0851-07 | — | cohortMD1 | 0.885 |
| 3 | TCGA-O2-A52S-01A-11R-A262-07 | — | cohortSQ2 | 0.874 |
| 4 | SRR650180 | — | — | 0.859 |
| 5 | 3d1f89ec-ac0b-40f8-ac89-ed0c2d4967b7 | — | — | 0.858 |
| 6 | BS_TZVFR600 | Med | Medulloblastoma | 0.858 |
| 7 | TCGA-E9-A22G-01A-11R-A157-07 | — | E | 0.856 |
| 8 | TCGA-58-A46M-01A-11R-A24H-07 | — | cohortSQ2 | 0.850 |
| 9 | 20030039.TNBC | — | E | 0.848 |
| 10 | R28 | — | — | 0.847 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.570 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.520 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.500 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.460 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.360 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.260 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.250 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.240 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.190 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.150 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.120 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.110 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.100 | Idelalisib | — uncovered |
| PEROXISOME | 0.090 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.070 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.070 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.050 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.030 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.020 | Inavolisib | — uncovered |